Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma

• Asıl Yazarlar: Jing-Yu Hou (Yazar), Ya-ting Xiao (Yazar), Jing-Bo Huang (Yazar), Xin-Hua Jiang (Yazar), Kai Jiang (Yazar), Xun Li (Yazar), Li Xu (Yazar), Min-Shan Chen (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: The RESORCE trial reported that regorafenib was effective as the second-line treatment for patients with hepatocellular carcinoma (HCC) after progression on sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice.Objective: We...